Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Jazz Pharmaceuticals plc publishes a filing, an earnings call transcript or a press release.

Get JAZZ alerts

About Rob Iannone

Rob Iannone has spoken on 3 earnings calls and 2 other investor events across 1 company, most recently for Jazz Pharmaceuticals plc on November 2, 2026. Jazz Pharmaceuticals plc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Jazz Pharmaceuticals plc includes Bruce Cozadd (CEO and Board Member), Renee D. Gala (CEO), Renee Gala (CEO, COO and Board Member) and 7 others.

Rob Iannone on recent calls

“The FDA approval of Zihara is a pivotal moment for JAS and represents a paradigm shift for the treatment of first-line HER2-positive metastatic GEA. Slide 14 illustrates how we expect the Horizon Regimen to transform legacy standards of care and reshaped the management of this aggressive cancer.”
Other, Q3 2026 Jazz Pharmaceuticals Earnings Conference Call ·
“This was my eighth ASCO as Jazz CMO and head of R&D. You know, when I started, as you said, we had some important products in oncology, niche products like Defetelio at the time, Irwin Ace and Vixios and we had Xyrem not yet Xywave and I came to jazz really to build an innovative biopharma company and really expand…”
Other, 2026 Jefferies Healthcare Conference ·
“I'm the chief medical officer, not chief commercial officer.”
Other, 2026 RBCCM Global Healthcare Conference ·
“I just point out that sometimes it's hard to judge progression in these patients. And then, as you point out, Once it's clinically apparent, in addition to imaging, patients may rapidly progress and not benefit from second-line therapy.”
Other, Jazz Pharmaceuticals plc Q1 FY2026 Earnings Call ·
“2025 was a transformative year across our R&D pipeline, and we look to build on this momentum in 2026, starting with the practice-changing data we presented at ASCO-GI on slide 15.”
Other, Jazz Pharmaceuticals plc Q4 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Jazz Pharmaceuticals plc

Recent activity